Scholar Rock Holding Corporation (SRRK)
| Market Cap | 5.80B +77.8% |
| Revenue (ttm) | n/a |
| Net Income | -408.73M |
| EPS | -3.21 |
| Shares Out | 119.83M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,048,978 |
| Open | 46.40 |
| Previous Close | 46.45 |
| Day's Range | 45.90 - 48.46 |
| 52-Week Range | 27.07 - 51.63 |
| Beta | 0.71 |
| Analysts | Strong Buy |
| Price Target | 55.50 (+14.69%) |
| Earnings Date | May 7, 2026 |
About SRRK
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company’s novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFβ) superfamily has enabled the development of a proprietary platform. This platform is used for the development of monoclonal antibodies that locally and selectively target the precursor, or laten... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for SRRK stock is "Strong Buy." The 12-month stock price target is $55.5, which is an increase of 14.69% from the latest price.
News
JPMorgan places Scholar Rock on ‘Positive Catalyst Watch’
JPMorgan placed a “Positive Catalyst Watch” on shares of Scholar Rock (SRRK) with an Overweight rating and $56 price target The firm is “very pleased” the apitegromab applicating for the
Scholar Rock price target raised to $55 from $53 at Barclays
Barclays raised the firm’s price target on Scholar Rock (SRRK) to $55 from $53 and keeps an Overweight rating on the shares.
Scholar Rock price target raised to $65 from $58 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Scholar Rock (SRRK) to $65 from $58 and keeps a Buy rating on the shares. The regulatory and commercial updates reinforce confidence
Scholar Rock Holding Earnings Call Transcript: Q1 2026
FDA accepted the BLA for apitegromab with two fill-finish facilities, setting a PDUFA date of September 30, 2026. Commercial launch preparations are advanced in the U.S. and Europe, with strong financial positioning and a robust pipeline. Regulatory and supply chain milestones are on track.
Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additi...
Scholar Rock to Present at the BofA Securities 2026 Health Care Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additi...
Scholar Rock initiated with a Buy at Canaccord
Canaccord analyst Gary Nachman last night initiated coverage of Scholar Rock (SRRK) with a Buy rating and $62 price target The company’s lead product apitegromab is nearing approval and launch
Scholar Rock initiated with a Buy at Canaccord
Canaccord initiated coverage of Scholar Rock (SRRK) with a Buy rating and $62 price target
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 89,304 shares of its common sto...
Scholar Rock to Report First Quarter 2026 Financial Results on May 7, 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026, before the financial markets open. The...
Scholar Rock price target raised to $57 from $54 at Jefferies
Jefferies raised the firm’s price target on Scholar Rock (SRRK) to $57 from $54 and keeps a Buy rating on the shares. Scholar Rock resubmitted its apitegromab biologics license application
Scholar Rock price target raised to $58 from $51 at BofA
BofA analyst Tazeen Ahmad raised the firm’s price target on Scholar Rock (SRRK) to $58 from $51 and keeps a Buy rating on the shares. Scholar Rock resubmitted its BLA
Scholar Rock resubmission ‘material de-risking event,’ says H.C. Wainwright
H.C. Wainwright analyst Andres Maldonado keeps a Buy rating on Scholar Rock (SRRK) with a $58 price target after the company announced the resubmission of its biologics license application for
Scholar Rock price target raised to $60 from $53 at Raymond James
Raymond James analyst Martin Auster raised the firm’s price target on Scholar Rock (SRRK) to $60 from $53 and keeps a Strong Buy rating on the shares. Scholar Rock announced
What Sent Scholar Rock Holding Stock (SRRK) Higher Today?
Scholar Rock Holding stock rallied on Tuesday alongside plans to resubmit a BLA for its spinal muscular atrophy treatment.
Scholar Rock up 12% at $48.27 after resubmitting BLA to FDA for apitegromab
08:40 EDT Scholar Rock (SRRK) up 12% at $48.27 after resubmitting BLA to FDA for apitegromab
Scholar Rock Holding Transcript: Status update
Apitegromab’s BLA has been resubmitted to the FDA with two fill-finish facilities, offering dual paths to approval and robust supply chain flexibility. Launch preparations are advanced, with sufficient inventory and payer engagement underway. EMA review is on track for mid-2026.
Scholar Rock resubmits BLA to FDA for apitegromab
Scholar Rock (SRRK) announced it has resubmitted the Biologics License Application, BLA, for apitegromab for the treatment of children and adults with Spinal Muscular Atrophy, SMA, to the U.S. Food
Scholar Rock Resubmits Biologics License Application (BLA) to FDA for Apitegromab for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additi...
Scholar Rock extends rally after Cantor note, shares up 14% to $45.34
15:57 EDT Scholar Rock (SRRK) extends rally after Cantor note, shares up 14% to $45.34
Scholar Rock jumps 8% after Cantor says Genentech stopped SMA drug
Scholar Rock (SRRK) in afternoon trading is up $3.10 to $42.89.
Scholar Rock price target raised to $50 from $47 at JPMorgan
JPMorgan raised the firm’s price target on Scholar Rock (SRRK) to $50 from $47 and keeps an Overweight rating on the shares. The firm updated the company’s model ahead of
Scholar Rock Holding Transcript: Barclays 28th Annual Global Healthcare Conference
The company is preparing for U.S. and European launches of its first-in-class myostatin inhibitor for SMA, supported by strong clinical data and a robust financial position. Regulatory delays are being addressed, with commercial and pipeline expansion plans advancing globally.
Scholar Rock Holding Transcript: Leerink Global Healthcare Conference 2026
Apitegromab's approval was delayed due to manufacturing compliance, but remediation and regulatory engagement are progressing, with a 2026 U.S. launch targeted. Commercial and supply chain readiness are strong, global expansion is planned, and financial resources are robust.